Status:
UNKNOWN
Clinical Evaluation of Detection of High Risk HPV in Urine
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Hangzhou Mingze Medical Research Co., Ltd.
Beijing Tsingke Biological Technology Co., Ltd. Hangzhou Branch
Conditions:
Human Papillomavirus Infection
Cervical Cancer
Eligibility:
FEMALE
20-65 years
Brief Summary
Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer....
Detailed Description
The urine high-risk HPV detection reagent (PCR-fluorescent probe method) developed by Hangzhou Newhorizon Health Technology Co., Ltd. can qualitatively detect 14 high-risk HPV DNA in human urine sampl...
Eligibility Criteria
Inclusion
- Women aged 20-65 years old;
- Have a history of sexual life;
- The patients were voluntarily enrolled in the group and signed an informed consent form.
Exclusion
- History of cervical conization, pelvic radiation and hysterectomy, acute inflammation of the reproductive tract, severe system disease or other malignant tumors;
- Pregnant and lactating women;
- The patient's compliance is poor or the researcher thinks it is not suitable for this study.
Key Trial Info
Start Date :
September 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05210348
Start Date
September 15 2021
End Date
May 1 2022
Last Update
January 27 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China
2
The Third Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
3
Nanjing First Hospital
Nanjing, Jiangsu, China